Press release
Insmed Reports First Quarter 2021 Financial Results and Provides Business Update
--ARIKAYCE® (amikacin liposome inhalation suspension) Approved in Japan for Patients with NTM Lung Disease Caused by MAC Who Did Not Sufficiently Respond to
About this update from Insmed Incorporated
[{"type":"text","content":"--ARIKAYCE® (amikacin liposome inhalation suspension) Approved in Japan for Patients with NTM Lung Disease Caused by MAC Who Did Not Sufficiently Respond to Prior Treatment with a Multidrug Regimen--\n --ARIKAYCE European Launch Under Way with Commercial Sales in Germany and the Netherlands--\n --Enrollment Progresses in Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis and in Post-Marketing ARISE and ENCORE Studies of ARIKAYCE in Frontline NTM Lung Disease Caused by MAC--\n --Treprostinil Palmitil Inhalation Powder (TPIP) Advancing to Phase 2 Development in Pulmonary Arterial Hypertension (PAH)--\n --ARIKAYCE Total Revenue of $40.2 Million for the First Quarter 2021--\n\n\n BRIDGEWATER, N.J., May 6, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the first quarter ended March 31, 2021 and provided a business update. \n\"Insmed is off to a strong start in 2021, with important advancements across each of our three programs and our earlier-stage research activities, as well as meaningful progress in the buildout of our global organization,\" commented Will Lewis, Chair and Chief Executive Officer of Insmed. \"In the first quarter of the year, we were very pleased to secure approval of ARIKAYCE in Japan—the third major territory where our lead product is now approved. Despite the ongoing challenges of COVID-19, we demonstrated steady ARIKAYCE performance in the U.S. and advanced our European launch. We continue to enroll patients in both the Phase 3 ASPEN study of brensocatib in patients with bronchiectasis and the ARIKAYCE frontline clinical trial program in patients with NTM lung disease, and are working to advance TPIP to Phase 2 clinical development. I am very proud of the Insmed team's steadfast dedication to the ambitious patient-centered vision we have set for this company.\" \nRecent Corporate Developments & Program Highlights \nARIKAYCE \nARIKAYCE was granted approval by Japan's Ministry of Health, Labour, and Welfare on March 23, 2021, for the treatment of patients with nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC) who did not sufficiently respond to prior treatment with a multidrug regimen. The launch ...